Kakyung Kim

Archives
Log in
Subscribe
October 10, 2026

๐Ÿ“ˆ econ-radar 2026-10-10 ยท FDA ๊ฐ€์†์Šน์ธ(Accelerated Approval)

๐Ÿ“ˆ econ-radar 2026-10-10 ยท FDA ๊ฐ€์†์Šน์ธ(Accelerated Approval)

๐Ÿ“ˆ econ-radar ๋ฐ์ผ๋ฆฌ

2026-10-10

์ œ์•ฝยท๋ฐ”์ด์˜คยทAI์— ๋ฌด๊ฒŒ๋ฅผ ๋‘” ๊ฒฝ์ œ ๋ฐ์ผ๋ฆฌ โ€” ์‚ฐ์—…๊ตฌ์กฐยทํˆฌ์žยท์‹œ์žฅ 3๋ Œ์ฆˆ

At a Glance

๐Ÿ’ฐ ์–ด๋‹์Šค ์‹œ์ฆŒ์ด ์‚ฌํ˜ ์•ž์œผ๋กœ ๋‹ค๊ฐ€์™”๋‹ค. S&P 500์€ ์‚ฌ์ƒ ์ตœ๊ณ ์— 4ํฌ์ธํŠธ ์ฐจ์ด๊นŒ์ง€ ์ ‘๊ทผํ–ˆ๊ณ , ๋‹ค์Œ ์ฃผ CPI(10/14)์™€ ๋น…๋ฑ…ํฌ ์‹ค์ (10/13)์ด ์ด ๊ฑฐ๋ฆฌ๋ฅผ ์ขํž์ง€ ๋ฒŒ๋ฆด์ง€ ๊ฒฐ์ •ํ•œ๋‹ค.

๐Ÿญ FDA๊ฐ€ ADC ๊ฐ€์†์Šน์ธ์— ๋ธŒ๋ ˆ์ดํฌ๋ฅผ ๋ฐŸ๋Š” ํŒจํ„ด์ด ๊ตณ์–ด์ง€๋Š” ๊ฐ€์šด๋ฐ, ํ™•์ฆ 3์ƒ ๋ฐ์ดํ„ฐ๋ฅผ ๊ฐ–์ถ˜ Tecentriq๋Š” ๊ฒฐ์žฅ์•” ๋ณด์กฐ์š”๋ฒ•์— ์ง„์ž…ํ–ˆ๋‹ค. ๊ฐ™์€ ๋‚ , ๋‘ ํ’ˆ๋ชฉ์˜ ์šด๋ช…์ด ์—‡๊ฐˆ๋ ธ๋‹ค.

๐Ÿš€ Alteogen์ด Novartis์™€ ์˜ฌํ•ด ๋„ค ๋ฒˆ์งธ SC(ํ”ผํ•˜์ฃผ์‚ฌ) ์ „ํ™˜ ํ”Œ๋žซํผ ๊ณ„์•ฝ์„ ์ฒด๊ฒฐํ–ˆ๋‹ค. Halozyme์ด ์‚ฌ์‹ค์ƒ ๋…์ ํ•˜๋˜ ์‹œ์žฅ์— ํ•œ๊ตญ์‚ฐ ๋Œ€์•ˆ์ด ์ž๋ฆฌ๋ฅผ ์žก์•„๊ฐ€๊ณ  ์žˆ๋‹ค.

Today's Top 5

Market

1. S&P 500 ์ฃผ๊ฐ„ ๋งˆ๊ฐ 7,812pts ยท ๋ฏธ 10๋…„๋ฌผ 5.24% โ€” ์–ด๋‹์Šค ์‹œ์ฆŒ D-3

10์›” 9์ผ(๊ธˆ) S&P 500์ด +0.59% ์˜ค๋ฅธ 7,812ํฌ์ธํŠธ๋กœ ํ•œ ์ฃผ๋ฅผ ๋งˆ์ณค๋‹ค. ์ฃผ์ค‘ 5.35%๊นŒ์ง€ ์น˜์†Ÿ์•˜๋˜ 10๋…„๋ฌผ ๊ตญ์ฑ„ ์ˆ˜์ต๋ฅ ์ด 5.24%๋กœ 11bp ๋‚ด๋ฆฌ์ž ๊ธฐ์ˆ ์ฃผ๊ฐ€ ๋ฐ˜๋“ฑ์„ ์ด๋Œ์—ˆ๋‹ค. ์‚ฌ์ƒ ์ตœ๊ณ (7,816.70pts, 8/13)์™€์˜ ๊ฒฉ์ฐจ๋Š” 4.7ํฌ์ธํŠธ๋‹ค. 2๋…„๋ฌผ 4.80%, 30๋…„๋ฌผ 5.61% ์ˆ˜์ค€์ด๋‹ค.

โ†— TheStreet 10/9 ๋งˆ๊ฐ

SemiconductorAI

2. TSMC Q3 ๋งค์ถœ $46.7B(์•ฝ 64์กฐ5,000์–ต์›) +50% YoY โ€” AI ๋ฐ˜๋„์ฒด ๊ณต๊ธ‰๋ง ๋ถ„๊ธฐ ์ตœ๋Œ€

TSMC๊ฐ€ 10์›” 8์ผ Q3 2026 ๋งค์ถœ ์ž ์ •์น˜๋ฅผ ๊ณต๊ฐœํ–ˆ๋‹ค. NT$1.49์กฐ(US$46.71B)๋กœ ๋ถ„๊ธฐ ์‚ฌ์ƒ ์ตœ๋Œ€๋ฅผ ๊ฒฝ์‹ ํ–ˆ๊ณ  LSEG ์ปจ์„ผ์„œ์Šค๋ฅผ ์ƒํšŒํ–ˆ๋‹ค. 9์›” ์›”๋ณ„ ๋งค์ถœ์€ NT$511.86B(+54.6% YoY)๋กœ ๋‘ ๋‹ฌ ์—ฐ์† NT$500B๋ฅผ ๋„˜์—ˆ๋‹ค. 2026๋…„ ์—ฐ๊ฐ„ ์„ค๋น„ํˆฌ์ž(capex)๋Š” 600~640์–ต๋‹ฌ๋Ÿฌ(์•ฝ 82์กฐ8,000์–ต~88์กฐ3,000์–ต์›) ๊ณ„ํš์„ ์œ ์ง€ํ•œ๋‹ค. ์ „์ฒด ์ด์ต๋ฅ ๊ณผ Q4 ๊ฐ€์ด๋˜์Šค๋Š” 10์›” 15์ผ ์‹ค์  ์ฝœ์—์„œ ๊ณต๊ฐœ๋  ์˜ˆ์ •์ด๋‹ค.

โ†— HeyGoTrade TSMC Q3

Bio

3. Roche Tecentriq, dMMR/MSI-H Stage III ๊ฒฐ์žฅ์•” FDA ์Šน์ธ โ€” Keytruda์™€ ๊ฒฝ์Ÿ ๊ตฌ๋„

FDA๊ฐ€ 10์›” 8์ผ Roche(Genentech)์˜ Tecentriq(์•„ํ…Œ์กธ๋ฆฌ์ฃผ๋ง™)์™€ FOLFOX6 ๋ณ‘์šฉ์„ ์ ˆ์ œ ํ›„ dMMR/MSI-H(๊ฒฐํ•จ ์žˆ๋Š” ๋ถˆ์ผ์น˜ ๋ณต๊ตฌ/๊ณ ๋„ ๋ฏธ์„ธ์œ„์„ฑ ๋ถˆ์•ˆ์ •์„ฑ) Stage III ๊ฒฐ์žฅ์•” ๋ณด์กฐ์š”๋ฒ•์œผ๋กœ ์Šน์ธํ–ˆ๋‹ค. Phase 3 ATOMIC์—์„œ ์žฌ๋ฐœยท์‚ฌ๋ง ์œ„ํ—˜ 50% ๊ฐ์†Œ, 36๊ฐœ์›” ๋ฌด๋ณ‘์ƒ์กด์œจ(DFS) 86% ๋Œ€ 76%๋ฅผ ์ž…์ฆํ–ˆ๋‹ค. SC(ํ”ผํ•˜์ฃผ์‚ฌ) ์ œํ˜• Tecentriq Hybreza๋„ 12์„ธ ์ด์ƒยท์ฒด์ค‘ 40kg ์ด์ƒ ํ™˜์ž์— ๋™์‹œ ์Šน์ธ๋๋‹ค. Tecentriq์˜ ๋ฏธ๊ตญ ๋‚ด 12๋ฒˆ์งธ ์ ์‘์ฆ์ด๋‹ค.

โ†— OncLive Tecentriq 10/8

ADC

4. I-DXd BLA ์ž์ง„ ์ฒ ํšŒ ๊ต์ • โ€” ADC ๊ฐ€์†์Šน์ธ ๊ฒฝ๋กœ ํ˜‘์†Œํ™” ํŒจํ„ด ์žฌํ™•์ธ

์˜ค๋Š˜(10/10)์ด ifinatamab deruxtecan(I-DXd, Daiichi SankyoยทMerck)์˜ ์›๋ž˜ PDUFA ๋ชฉํ‘œ์ผ์ด์ง€๋งŒ, BLA๋Š” ์ด๋ฏธ 9์›” 25์ผ ์ž์ง„ ์ฒ ํšŒ๋๋‹ค. FDA๊ฐ€ Phase 2 IDeate-Lung01(ORR 48.2%, 187๋ช…)์ด ๊ฐ€์†์Šน์ธ(Accelerated Approval) ๊ธฐ์ค€์„ ์ถฉ์กฑํ•˜์ง€ ๋ชปํ•œ๋‹ค๊ณ  ํŒ๋‹จํ•œ ๋ฐ ๋”ฐ๋ฅธ ๊ฒƒ์ด๋‹ค. 10/6ยท10/8ยท10/9 ํŒŒ์ผ์—์„œ PDUFA D-4/D-2/D-1๋กœ ์ถ”์ ๋๋˜ ๊ฒƒ์€ ์˜ค๊ธฐ๋กœ, ์˜ค๋Š˜ ๊ณต์‹ ๊ต์ •ํ•œ๋‹ค. Phase 3 IDeate-Lung02(ES-SCLC 2์ฐจ ์น˜๋ฃŒ, ํ™”ํ•™์š”๋ฒ• ๋Œ€๋น„ ๊ฒ€์ฆ์  ์ž„์ƒ) ๋“ฑ๋ก์€ ๋งˆ๊ฐ ๋‹จ๊ณ„๋กœ ์•Œ๋ ค์กŒ๋‹ค.

โ†— OncLive I-DXd ์ฒ ํšŒ 9/25

Market

5. Alteogen-Novartis ALT-B4 $3.22B(์•ฝ 4์กฐ4,400์–ต์›) โ€” SC ํ”Œ๋žซํผ 4๋ฒˆ์งธ ๋”œ + ํ•œ๊ตญ ์ด์ค‘ ๊ฐ€๊ฒฉ ์ œ๋„

Alteogen(์—์ด์—˜ํ‹ฐ์ด์  )์ด 9์›” 2์ผ Novartis์™€ ALT-B4(berahyaluronidase alfa, ๋ฒ ๋ผํžˆ์•Œ๋ฃจ๋กœ๋‹ˆ๋‹ค์ œ ์•ŒํŒŒ) ๊ธฐ๋ฐ˜ Hybrozyme ํ”Œ๋žซํผ์„ ํ™œ์šฉํ•œ ๋‹ค์ˆ˜ ๋ฐ”์ด์˜ค์˜์•ฝํ’ˆ์˜ SC ์ „ํ™˜์— ๋Œ€ํ•œ ์˜ต์…˜ยท๋ผ์ด์„ ์Šค ๊ณ„์•ฝ์„ ์ฒด๊ฒฐํ–ˆ๋‹ค. ๊ณ„์•ฝ ์ด ๊ฐ€์น˜๋Š” ์ตœ๋Œ€ 32.2์–ต๋‹ฌ๋Ÿฌ(์•ฝ 4์กฐ4,400์–ต์›)๋กœ, 2026๋…„ ๋“ค์–ด ๋„ค ๋ฒˆ์งธ ๊ธ€๋กœ๋ฒŒ ๋น…ํŒŒ๋งˆ ๋”œ์ด๋‹ค. ๋ฐฐ๊ฒฝ์—๋Š” ํ•œ๊ตญ ์˜์•ฝํ’ˆ ์ด์ค‘ ๊ฐ€๊ฒฉ ์ œ๋„(Dual Price System, 2026๋…„ 6์›” ์‹œํ–‰)๋„ ์žˆ๋‹ค. ๊ณต๊ฐœ ๋ชฉ๋ก ๊ฐ€๊ฒฉ์„ A8 ์ฐธ์กฐ๊ตญ(๋ฏธยท์˜ยท๋… ๋“ฑ) ์ˆ˜์ค€์œผ๋กœ ์œ ์ง€ํ•˜๊ณ , ์‹ค๊ฑฐ๋ž˜๊ฐ€๋Š” ๊ฑด๊ฐ•๋ณดํ—˜๊ณต๋‹จ(NHIS)๊ณผ ๊ธฐ๋ฐ€ ํ˜‘์ƒ์œผ๋กœ ๊ฒฐ์ •ํ•˜๋Š” ๋ฐฉ์‹์œผ๋กœ, ํ•œ๊ตญ ์•ฝ๊ฐ€๊ฐ€ ๊ธ€๋กœ๋ฒŒ ์ฐธ์กฐ ๊ฐ€๊ฒฉ์„ ๋Œ์–ด๋‚ด๋ฆฌ๋˜ ๊ตฌ์กฐ๋ฅผ ์™„ํ™”ํ•œ๋‹ค.

โ†— OutsourcedPharma Alteogen 9/2

๐Ÿ—ฃ ์˜ค๋Š˜์˜ ํ™”์ œ

FDA ๊ฐ€์†์Šน์ธ์€ "๋น ๋ฅธ ํ—ˆ๊ฐ€ + ํ™•์ฆ ์˜๋ฌด"์˜ ๊ฑฐ๋ž˜์ธ๋ฐ, ํ™•์ฆ ๊ธฐ์ค€์ด ์—„๊ฒฉํ•ด์ง€๋ฉด์„œ Phase 2 ORR ๋‹จ๋…์œผ๋กœ ํ†ต๊ณผํ•˜๋˜ ADC ๊ฒฝ๋กœ๊นŒ์ง€ ์ข์•„์กŒ๋‹ค.

์ „์ฒด ๋ฆฌํฌํŠธ ๋ณด๊ธฐ โ†’

Deep Dive ยท Demand ยท Investment ยท Companies ยท Sources ์ „์ฒด๋Š” ์œ„ ๋งํฌ์—์„œ ๋ณด์‹ค ์ˆ˜ ์žˆ์Šต๋‹ˆ๋‹ค.

ํ…”๋ ˆ๊ทธ๋žจ @econradar ๋กœ๋„ ๋ฐ›๊ธฐ

econ-radar ยท 2026-10-10

ํˆฌ์ž ์ฐธ๊ณ ์šฉ ์ •๋ณด์ž…๋‹ˆ๋‹ค. ์ตœ์ข… ํŒ๋‹จ๊ณผ ์ฑ…์ž„์€ ๋ณธ์ธ์—๊ฒŒ ์žˆ์Šต๋‹ˆ๋‹ค.

Don't miss what's next. Subscribe to Kakyung Kim:
โ† Newer ๐Ÿ“ˆ econ-radar 2026-10-11 ยท mRNA ๊ฐœ์ธํ™” ํ•ญ์•”๋ฐฑ์‹ (personalized mRNA cancer vaccine) Older โ†’ ๐Ÿ“ˆ econ-radar 2026-10-09 ยท ์ค‘๋ฆฝ๊ธˆ๋ฆฌ(r*)์™€ ๊ณ ๊ธˆ๋ฆฌ ๋‰ด๋…ธ๋ฉ€: ์ธํ”Œ๋ ˆ์ด์…˜ ์žฌ์ ํ™” vs. ์—ฐ์ฐฉ๋ฅ™ ๋ถ„๊ธฐ์ 
Powered by Buttondown, the easiest way to start and grow your newsletter.